NCT00897949

MK0462 in Treatment of Migraine With Recurrence (MK0462-022)

A Randomized, Triple-Blind, Double-Dummy, Placebo-Controlled, Parallel Groups, Outpatient Study to Examine the Safety and Efficacy of MK0462 10 mg p.o. and MK0462 5 mg p.o. for the Treatment of Acute Migraine and Migraine Recurrence

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,473 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo. The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.

Conditions

• Migraine Headache

Interventions

Type	Name	Description
DRUG	rizatriptan benzoate (MK0462)	Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
DRUG	Comparator: placebo	Placebo to rizatriptan

Timeline

• Start date: 1995-03-01
• Primary completion: 1996-01-01
• Completion: 1996-07-01
• First posted: 2009-05-12
• Last updated: 2022-02-03
• Results posted: 2011-05-04